- About ERC
- Projects & figures
- Managing your project
Acetylsalicylic acid, most commonly known as aspirin, was already part of the Egyptian pharmacopeia, used also in ancient Greece and in the Middle Ages to break fevers. Taken all over the world to kill pain and reduce inflammation, today aspirin helps to prevent heart attacks, strokes and blood clots. Its emerging role in preventing and treating cancer is on the rise too. But how does this drug act on your blood cells? ERC grantee Prof Valerie O’Donnell works on the answer.
Prof. Michael Schneider is a leading authority in the field of cardiac molecular biology. In 2008, he obtained an ERC grant to identify the mechanisms governing self-renewal of cardiac progenitor cells, a population of stem cells located in the heart itself that might be exploited to play a key role in regenerating this vulnerable organ in heart disease. With his team at Imperial College London, he has now identified a stem cell injection that could mend broken hearts, a discovery in the field of regenerative medicine published this week in Nature Communications.
In 2012, 2.8 million people in the EU were diagnosed with cancer. It is the second most common cause of death in the Union – three out of 10 deaths for men, and two out of 10 deaths for women – a figure that is expected to rise due to the ageing European population. Dr Danijela Matic Vignjevic’s STARLIN project is using ERC funding to understand how normal cells become cancerous and spread.
The ability to fine-tune the functioning of blood vessels and the circulatory system is essential for combating the remodelling of the arteries that leads to heart attacks and strokes. It is also needed for the controlled repair of blood vessels after injury – which may otherwise result in a number of serious conditions. ERC grantee Professor Stefanie Dimmeler and her team at Frankfurt University are studying the role ribonucleic acid (RNA) plays in fine-tuning vascular functions – with the aim of developing new therapies for cardiovascular diseases, which are the most prevalent in Europe, due to growing obesity and longer lifespans.
Significant progress has been made in understanding breast tumour biology. However statistics indicate that the number of breast cancer patients and victims will continue to increase. Dr. Bentires-Alj, ERC Starting Grantee at the Friedrich Miescher Institute for Biomedical Research in Basel, and his team are studying the roles of the still under-explored family of protein-tyrosine phosphatases (PTPs) in both normal breast development and cancers. In a recent study, published in Nature Medicine in March 2012, Dr Bentires-Alj's team have revealed the fundamental role of the protein phosphatase SHP2 in breast cancer proliferation, invasion and metastasis.
The genetic heredity a person is born with isn't as impossible to change as one might think. In a study published in Cell Metabolism on 7 March 2012 Juleen Zierath, an ERC Advanced grantee 2008, and her team of researchers from the Karolinska Institutet in Sweden showed that when healthy but inactive men and women are made to exercise it actually alters chemical marks on their DNA - in a matter of minutes.